Core Viewpoint - The company, He Yu-B (02256), has seen its stock price increase by over 10% during trading, currently up by 8.44% at HKD 13.11, with a trading volume of HKD 34.21 million. This surge is attributed to the announcement that its self-developed FGFR4 inhibitor, Irpagratinib (ABSK-011), has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC) [1]. Group 1 - He Yu-B announced that Irpagratinib has received orphan drug designation from the EMA, which will support its clinical development, registration, and commercialization in Europe [1]. - Irpagratinib is a highly selective, orally administered small molecule FGFR4 inhibitor developed by He Yu-B [1]. - The drug has also received orphan drug designation and fast track designation from the U.S. FDA, as well as breakthrough therapy designation from the NMPA in China [1].
港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格